Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Gross Margin (2016 - 2025)

Protalix BioTherapeutics has reported Gross Margin over the past 16 years, most recently at 49.36% for Q4 2025.

  • Quarterly results put Gross Margin at 49.36% for Q4 2025, down 2931.0% from a year ago — trailing twelve months through Dec 2025 was 48.82% (down 564.0% YoY), and the annual figure for FY2025 was 48.82%, down 564.0%.
  • Gross Margin for Q4 2025 was 49.36% at Protalix BioTherapeutics, down from 53.37% in the prior quarter.
  • Over the last five years, Gross Margin for PLX hit a ceiling of 82.47% in Q2 2023 and a floor of 15.54% in Q4 2023.
  • Median Gross Margin over the past 5 years was 53.37% (2025), compared with a mean of 52.51%.
  • Biggest five-year swings in Gross Margin: tumbled -5698bps in 2021 and later soared 6312bps in 2024.
  • Protalix BioTherapeutics' Gross Margin stood at 63.18% in 2021, then rose by 14bps to 72.18% in 2022, then crashed by -78bps to 15.54% in 2023, then soared by 406bps to 78.67% in 2024, then crashed by -37bps to 49.36% in 2025.
  • The last three reported values for Gross Margin were 49.36% (Q4 2025), 53.37% (Q3 2025), and 62.51% (Q2 2025) per Business Quant data.